IL308695A - Anti-NKG2A antibodies and compositions - Google Patents

Anti-NKG2A antibodies and compositions

Info

Publication number
IL308695A
IL308695A IL308695A IL30869523A IL308695A IL 308695 A IL308695 A IL 308695A IL 308695 A IL308695 A IL 308695A IL 30869523 A IL30869523 A IL 30869523A IL 308695 A IL308695 A IL 308695A
Authority
IL
Israel
Prior art keywords
compositions
nkg2a antibodies
nkg2a
antibodies
Prior art date
Application number
IL308695A
Other languages
English (en)
Hebrew (he)
Inventor
Randi Westh Hansen
Franziska Katharina Uhlenbrock
Nikolaj Dietrich
Anne Worsaae
Michael Monrad Grandal
Original Assignee
Servier Lab
Randi Westh Hansen
Franziska Katharina Uhlenbrock
Nikolaj Dietrich
Anne Worsaae
Michael Monrad Grandal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Randi Westh Hansen, Franziska Katharina Uhlenbrock, Nikolaj Dietrich, Anne Worsaae, Michael Monrad Grandal filed Critical Servier Lab
Publication of IL308695A publication Critical patent/IL308695A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL308695A 2021-06-01 2022-05-31 Anti-NKG2A antibodies and compositions IL308695A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163195470P 2021-06-01 2021-06-01
PCT/EP2022/064703 WO2022253805A1 (en) 2021-06-01 2022-05-31 Anti-nkg2a antibodies and compositions

Publications (1)

Publication Number Publication Date
IL308695A true IL308695A (en) 2024-01-01

Family

ID=82117230

Family Applications (1)

Application Number Title Priority Date Filing Date
IL308695A IL308695A (en) 2021-06-01 2022-05-31 Anti-NKG2A antibodies and compositions

Country Status (17)

Country Link
US (2) US12012450B2 (https=)
EP (1) EP4347651A1 (https=)
JP (1) JP2024520577A (https=)
KR (1) KR20240016991A (https=)
CN (1) CN117460748A (https=)
AR (1) AR126001A1 (https=)
AU (1) AU2022286617A1 (https=)
BR (1) BR112023024772A2 (https=)
CA (1) CA3222040A1 (https=)
CL (1) CL2023003562A1 (https=)
CO (1) CO2023015982A2 (https=)
IL (1) IL308695A (https=)
MX (1) MX2023014320A (https=)
PE (1) PE20240372A1 (https=)
PH (1) PH12023553123A1 (https=)
TW (1) TW202313683A (https=)
WO (1) WO2022253805A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024140820A1 (zh) * 2022-12-28 2024-07-04 浙江博锐生物制药有限公司 抗nkg2a抗体及其用途
WO2024260280A1 (en) * 2023-06-21 2024-12-26 Elpiscience (Suzhou) Biopharma, Ltd. Antibodies or antigen-binding fragments binding to nkg2a and uses thereof
CN121941711A (zh) * 2024-02-08 2026-04-28 翰思艾泰生物医药科技(武汉)股份有限公司 Nkg2a/cd94靶向抗体及其用途
CN121108342B (zh) * 2025-09-08 2026-03-03 北京明璨生物科技有限公司 包含抗体和nk细胞的组合物在治疗癌症中的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−６受容体に対する高親和性抗体
KR20100110864A (ko) * 2008-01-24 2010-10-13 노보 노르디스크 에이/에스 인간화된 항-인간 ｎｋｇ2ａ 모노클로날 항체
SG10202007781TA (en) 2014-09-16 2020-09-29 Innate Pharma Treatment Regimens Using Anti-NKG2A Antibodies
US10329348B2 (en) * 2014-10-23 2019-06-25 Innate Pharma Treatment of cancers using anti-NKG2A agents
WO2017046774A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
PH12018502112B1 (en) 2016-04-12 2024-03-27 Servier Lab Anti-tim-3 antibodies and compositions
US12534526B2 (en) 2018-11-07 2026-01-27 Shanghai Hyamab Biotech Co., Ltd. NKG2A antibody, preparation method therefor and application thereof
CN113316590B (zh) * 2018-11-16 2025-02-28 百时美施贵宝公司 抗nkg2a抗体及其用途

Also Published As

Publication number Publication date
US20220389100A1 (en) 2022-12-08
TW202313683A (zh) 2023-04-01
US12012450B2 (en) 2024-06-18
CN117460748A (zh) 2024-01-26
AU2022286617A1 (en) 2023-12-21
CO2023015982A2 (es) 2024-01-15
PE20240372A1 (es) 2024-03-05
EP4347651A1 (en) 2024-04-10
AR126001A1 (es) 2023-08-30
CA3222040A1 (en) 2022-12-08
WO2022253805A1 (en) 2022-12-08
JP2024520577A (ja) 2024-05-24
KR20240016991A (ko) 2024-02-06
BR112023024772A2 (pt) 2024-02-15
MX2023014320A (es) 2023-12-13
PH12023553123A1 (en) 2024-03-04
CL2023003562A1 (es) 2024-07-12
US20240294638A1 (en) 2024-09-05

Similar Documents

Publication Publication Date Title
IL308808A (en) Antibodies against CCR8 and their uses
SG11202100888WA (en) Anti-avb8 antibodies and compositions and uses thereof
IL290141A (en) Formulations of anti-pvrig antibodies and uses thereof
IL308695A (en) Anti-NKG2A antibodies and compositions
GB202017058D0 (en) Antibodies and uses thereof
PL4208045T3 (pl) Kompozycje i sposoby
IL307267A (en) ANTI-CD122 antibodies and their uses
IL310662A (en) Anti-CD161 antibodies and their uses
IL307940A (en) Anti-ADGRE2 antibodies and their uses
IL288830A (en) Methods for purifying an antibody and its preparations
GB202111040D0 (en) Compositions and methods
GB202108585D0 (en) Methods and compositions
IL307939A (en) Anti-CLEC12A antibodies and uses thereof
IL310329A (en) Preparations and methods for anti-PACAP antibodies
GB202004677D0 (en) Methods and compositions
IL312584A (en) ANTI-VISTA antibodies and their uses
IL310810A (en) Anti-ACVR2A antibodies and uses thereof
IL307233A (en) Anti-SEMA3A antibodies and uses thereof
IL304824A (en) Phosphorofol methods and preparations
IL308198A (en) Anti-IL-27 antibodies and uses thereof
GB202116554D0 (en) Methods and compositions
GB202110091D0 (en) Methods and compositions
IL326262A (en) Anti-GPRC5D antibodies and composition
EP4294530A4 (en) ANTI-VISTA ANTIBODIES AND USES THEREOF
GB202116704D0 (en) Antibodies and uses thereof